Nutrigenomics and Cancer

PDF - Export to EndNote - PubMed Central XML format - PubMed Central XML format

PMID: 23407612 (PubMed) - PMCID: PMC3558114 - View online: PubReader
Volume 1, Issue 1, April-June , Page 9 to 17
Monday, March 2, 2009 :Received , Saturday, April 18, 2009 :Accepted

  • Corresponding author Ph.D., Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran, P.O. Box: 19615-1177, Tel: +98 21 22432020, Fax: +98 21 22432021, E-mail:
    - Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR , Tehran, Iran

  • - Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR , Tehran, Iran

Abstract: Cancer incidence is projected to increase in the future and an effectual preventive strategy is required to face this challenge. Alteration of dietary habits is potentially an effective approach for reducing cancer risk. Assessment of biological effects of a specific food or bioactive component that is linked to cancer and prediction of individual susceptibility as a function of nutrient-nutrient interactions and genetics is an essential element to evaluate the beneficiaries of dietary interventions. In general, the use of biomarkers to evaluate individuals susceptibilities to cancer must be easily accessible and reliable. However, the response of individuals to bioactive food components depends not only on the effective concentration of the bioactive food components, but also on the target tissues. This fact makes the response of individuals to food components vary from one individual to another. Nutrigenomics focuses on the understanding of interactions between genes and diet in an individual and how the response to bioactive food components is influenced by an individual’s genes. Nutrients have shown to affect gene expression and to induce changes in DNA and protein molecules. Nutrigenomic approaches provide an opportunity to study how gene expression is regulated by nutrients and how nutrition affects gene variations and epigenetic events. Finding the components involved in interactions between genes and diet in an individual can potentially help identify target molecules important in preventing and/or reducing the symptoms of cancer.



Introduction :
It is believed that dietary habits as an important modifiable environmental factor, influence cancer risk and tumor behavior. It is estimated that diet influences about 30-40% of all cancer cases, however, the actual percentage is not known and depends on the specific type of cancer and the specific com-ponents of diet (1).
Many studies indicate that breast, prostate, liver, colon and lung cancers are linked to the dietary intakes (2). However, the linkage has not shown to be consistent perhaps due to the multifactorial and complex nature of cancer and the specificity of dietary constituents and their effects on genetic path-ways. Although excess calories are generally linked to enhanced cancer risk, many bio-active components in food can potentially provide protection at several stages during cancer development (2). Some of these bio-active components such as calcium, zinc, selenium, folate, vitamins C, D and E, caro-tenoids, flavonoids, indoles, allyl sulfur com-pounds, conjugated linoleic acid and N-3 fatty acids may influence carcinogen metabolism, cell signaling, cell cycle control, apoptosis, hormonal balance and angiogenesis (3). Studies of variations in cancer incidence among and within populations under similar dietary habits suggest that an individual’s res-ponse to food may reflect genetic predisposi-tion of an individual as well as differences in gene and protein expression patterns in the individual. Recently the effects of nutrition on DNA methylation and the role of epigenetic events in cancer prevention have also been reviewed (4).
Biology of cancer
Malignant cells are characterized by the upregulation or activation of many signaling pathways that are involved in proliferation, apoptosis, invasion and angiogenesis (5). In malignancy, many proteins and pathways are observed to be up regulated and opposing malignant behavior of cells.
Hanahan and Weinberg (6) have summar-ized the derangements in signaling that are required for the formation of a fully invasive tumor. These include:
  • Self-sufficiency in growth signals or ac-tivation of growth signals without the need for exogenous signals
  • Insensitivity to proliferation inhibiting sig-nals
  • Activation of survival pathways
  • Indefinite replication which leads to avoi-dance of terminal differentiation or sense-cence
  • Angiogenesis initiation
  • Invasion and metastasis
During the carcinogenic process, multiple oncogenic mutations occur that are often functionally redundant. It has been suggested that no single pathway appears to be the cause of cancer, therefore, multiple dietary and/or chemical interventions are likely to prevent cancer growth (5,7).
Individual foods and their constituents
Evidences suggest that foods offer advan-tages over their isolated constituents in treat-ment of cancer. This may be due to presence of multiple bioactive compounds within the food that exert additive or synergistic effects. For example, in treatment of human lung cancer cells which undergo apoptosis, whole green tea is more effective than the individual constituents of the green tea in inhibiting TNF-a release (8). These effects appear to be mediated through enhanced incorporation of the tea polyphenols into the cells. In a rat study in which prostate carcinogenesis was induced by N-methyl-N-nitrosourea (NMU)- testosterone, tomato powder was shown to inhibit carcinogenesis. These effects were suspected to be at the levels of absorption, retention, or metabolism (9). In another study a fat-soluble extract from vegetable powder was found to be more efficacious than ß-carotene in inhibiting cell proliferation in a lung cancer cell line (10). There have been also cases wherein, the foods were found not to be as effective as their isolated components, suggesting that the food may contain constituents that inhibit the cellular response. Although the mechanisms involved in these processes are no


References :
  1. Davis CD, Milner J. Frontiers in nutrigenomics, proteomics, metabolomics and cancer prevention. Mutat Res 2004;551(1-2):51-64.
  2. Davis CD. Nutritional Interactions: Credentialing of molecular targets for cancer prevention. Exp Biol Med 2007;232(2):176-183.
  3. Surh YJ. Cancer chemoprevention with dietary phyto-chemicals. Nat Rev Cancer 2003;3(10):768-780.
  4. Johaning GL, Heimburger DC, Piyathilake CJ. DNA methylation and diet in cancer. J Nutr 2002; 132(12):3814S-3818S.
  5. McCarty MF. Targeting multiple signaling path-ways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Can-cer Ther 2004;3(4):349-380.
  6. Hanahan D, Weinberg RA. The hallmarks of can-cer. Cell 2000;100(1):57-70.
  7. Manson MM. Inhibition of survival signalling by dietary polyphenols and indole-3-carbinol. Eur J Cancer 2005;41(13):1842-1853.
  8. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H. Synergistic effects of (epigallocatechin gallate with epicatechin, sulindac, or tamoxifen on cancer preventive activity in the human lung cancer cell line PC-9. Cancer Res 1999;59(1):44-47.
  9. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)- testosterone- treated rats fed tomato powder, lycopene, or energy restricted diets. J Natl Cancer Inst 2003;95(21): 1578-1586.
  10. Lu QJ, Huang CY, Yao SX, Wang RS, Wu XN. Effects of fat soluble extracts from vegetable powder and beta carotene on proliferation and apoptosis of lung cancer cell YTMLC-90. Biomed Environ Sci 2003;16(3):237-245.
  11. Thiagarajan DG, Bennink MR, Bourquin LD, Kavas FA. Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium. Am J Clin Nutr 1998;68(Suppl 6): 1394S-1399S.
  12. Roberts MA, Mutch DM, German JB. Genomics: food and nutrition. Curr Opin Biotechnol 2001;12 (5):516-522.
  13. Peregrin T. The new frontier of nutrition science: nu-trigenomics. J Am Diet Assoc 2001;101(11):1306.
  14. Elliott R, Ong TJ. Nutritional genomics. BMJ 2002;324(7351):1438-1442.
  15. Daniel H. Genomics and proteomics: importance for the future of nutrition research. Br J Nutr 2002; 87(Suppl 2):S305-311.
  16. van Ommen B, Stierum R. Nutrigenomics: exploi-ting systems biology in the nutrition and health arena. Curr Opin Biotechnol 2002;13(5):517-521.
  17. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPAR-? agonist rosiglitazone. J Lipid Res 2002;43 (11):1809-1817.
  18. MacBeath G. Protein microarrays and proteomics. Nature Genet 2002;32(Suppl):526-532.
  19. Grody WW. Molecular genetic risk screening. Annu Rev Med 2003;54:473-490.
  20. Bailey LB, Gregory JF. Polymorphisms of methyl-enetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999;129(5):919-922.
  21. Qi L, Cho YA. Gene environment interaction and obesity. Nutr Rev 2008;66(12):684-694.
  22. Dahlman I, Vaxillaire M, Nilsson M, Lecoeur C, Gu HF, Cavalcanti Proença C, et al. Estrogen receptor alpha gene variants associate with type 2 diabetes and fasting plasma glucose. Pharmaco-genet Genomics 2008;18(11):967-975.
  23. Ordovas JM, Shen J. Gene-environment inter actions and susceptibility to metabolic syndrome and other chronic diseases. J Periodontol 2008;79 (Suppl 8):1508-1513.
  24. Caprioli J, Mele C, Mossali C, Gallizioli L, Giachetti G, Noris M. Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hyper-tension. Can J Physiol Pharmacol 2008;86:(8): 505-510.
  25. Omer RE, Verhoef L, Van't Veer P, Idris MO, Kadaru AM, Kampman E, et al.. Peanut butter intake, GSTM1 genotype and hepatocellular carci-noma: a case-control study in Sudan. Cancer Causes Control 2001;12(1):23-32.
  26. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409(6822):928-933.
  27. Potter JD. At the interfaces of epidemiology, genetics and genomics. Nat Rev Genet 2001;2(2): 142-147.
  28. Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, et al. A high resolution recombination map of the human genome. Nat Genet 2002;31(3):241-247.
  29. Boomsma D, Busjahn A, Peltonen L. Classical twin studies and beyond. Nat Rev Genet 2002;3 (11):872-882.
  30. Davis CD, Milner JA. Diet and cancer prevention. In: Temple NJ, Wilson T, Jacobs DV, (eds). Nutritional Health: Strategies for disease preven-tion. Totowa: Humana Press; 2006,151-171.
  31. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3(10):768-780.
  32. Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 2009;7:1-21.
  33. Takeshita A, Koibuchi N, Oka J, Taguchi M, Shishiba Y, Ozawa Y. Bisphenol-A, an environ-mental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor mediated transcription. Eur J Endocrinol 2001;145 (4):513-517.
  34. LeCluyse EL. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 2001;134(3): 283-289.
  35. Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 2005;224(2): 171-184.
  36. Keum YS, Jeong WS, Kong AN. Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat Res 2004;555(1-2): 191-202.
  37. Milner JA. A historical perspective on garlic and cancer. J Nutr 2001;131(3s):1027S-1031S.
  38. Bartsch H. DNA adducts in human carcinogenesis: etiological relevance and structure activity relation-ship. Mutat Res 1996;340(2-3):67-79.
  39. Chao EC, Lipkin SM. Molecular models for the tissue specificity of DNA mismatch repair deficient carcino-genesis. Nucleic Acids Res 2006;34(3):840-852.
  40. Cooke MS, Evans MD, Dove R, Rozalski R, Gack-owski D, Siomek A, et al. DNA repair is respon-sible for the presence of oxidatively damaged DNA lesions in urine. Mutat Res 2005; 574(1-2):58-66.
  41. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
  42. Frisco S, Choi SW. Gene-nutrient interactions in one carbon metabolism. Curr Drug Metab 2005;6 (1):37-46.
  43. Astley SB, Elliott RM, Archer DB, Southon S. Evidence that dietary supplementation with caro-tenoids and carotenoid rich food modulate the DNA damage: repair balance in human lympho-cytes. Br J Nutr 2004;91(1):63-72.
  44. Moller P, Loft S. Interventions with anti oxidants and nutrients in relation to oxidative DNA damage and repair. Mutat Res 2004;551(1-2):79-89.
  45. Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell 2002;111 (7):923-925.
  46. Chen C, Kong AN. Dietary cancer chemo preven-tive compounds: from signaling and gene expres-sion to pharmacological effects. Trends Pharmacol Sci 2005;26(6):318-326.
  47. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000;21(5):857-864.
  48. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60(8):1051-1059.
  49. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E. Oxidative stress and cell signaling. Curr Med Chem 2004;11(9):1163-1182.
  50. Martin KR. Targeting apoptosis with dietary bio-active agents. Exp Biol Med 2006;231(2):117-129.
  51. Hu R, Kong AN. Activation of MAP kinases, apoptosis and nutrigenomics of gene expression elicited by dietary cancer-prevention compounds. Nutrition 2004;20(1):83-88.
  52. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407(6805):789-795.
  53. Watson RW, Fitzpatrick JM. Targeting apoptosis in prostate cancer: focus on caspases and inhibitors of apoptosis proteins. BJU Int 2005;96(Suppl 2): 30-34.
  54. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281(5381):1312-1316.
  55. Hofseth LJ, Ying L. Identifying and defusing weapons of mass inflammation in carcinogenesis. Biochem Biophys Acta 2006;1765(1):74-84.
  56. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3(4):276-285.
  57. Storz P. Reactive oxygen species in tumor progres-sion. Front Biosci 2005;10:1881-1896.
  58. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E. Oxidative stress and cell signaling. Curr Med Chem 2004;11(9):1163-82.
  59. Shany S, Levy Y, Lahav-Cohen M. The effects of 1alpha, 24 (S)-dihydroxyvitamin D (2) analog on cancer cell proliferation and cytokine expression. Steroids 2001;66(3-5):319-325.
  60. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995;49(11):1551-1556.
  61. Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 2001;296 (1):181-187.
  62. Davis JN, Kucuk O, Djuric Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents NF-kappaB activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 2001;30 (11):1293-1302.
  63. Manna SK, Aggarwal BB. All-trans-retinoic acid up regulates TNF receptors and potentiates TNF-induced activation of nuclear factors kappa B, activated protein-1 and apoptosis in human lung cancer cells. Oncogene 2000;19(17):2110-2119.
  64. Fayette J, Soria JC, Armand JP. Use of angio-genesis inhibitors in tumor treatment. Eur J Cancer 2005;41(8):1109-1116.
  65. Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/ fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16(2):159-178.
  66. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemo preven-tion. Cancer Res 2005;65(23):10637-10641.
  67. Pfeffer U, Ferrari N, Morini M, Benelli R, Noonan DM, Albini A. Antiangiogenic activity of chemo preventive drugs. Int J Biol Markers 2003;18(1): 70-74.
  68. Cockett MI, Murphy G, Birch ML, O’Connell JP, Crabbe T, Millican AT, et al. Matrix metalloprotei-nases and metastatic cancer. Biochem Soc Symp 1998;63:295-313.
  69. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 2006;231 (1):20-27.
  70. Rose DP, Connolly JM. Regulation of tumor angiogenesis by dietary fatty acids and eico-sanoids. Nutr Cancer 2000;37(2):119-127.
  71. Cao Y, Cao R, Brakenhielm E. Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 2002;13(7):380-390.
  72. Dulak J. Nutraceuticals as anti angiogenic agents: hope and reality. J Physiol Pharmacol 2005;56 (Suppl 1):51-67.
  73. Oak MH, El Bedoui J, Schini-Kerth VB. Anti angiogenic properties of natural polyphenols from red wine and green tea. J Nutr Biochem 2005;16 (1):1-8.